Abemaciclib: Difference between revisions

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

Revision as of 09:57, 23 October 2023 view source Alexander Berchansky (talk \| contribs) 29,637 edits No edit summary ← Older edit		Revision as of 10:01, 23 October 2023 view source Alexander Berchansky (talk \| contribs) 29,637 edits No edit summary Newer edit →
Line 1:		Line 1:
	<StructureSection load='' size='340' side='right' caption='Caption for this structure' scene=''>		<StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='10/1002442/Cv/1'>
	Abemaciclib, sold under the brand name Verzenio among others, is a medication for the treatment of advanced or metastatic breast cancers. It was developed by Eli Lilly and it acts as a CDK inhibitor selective for [[cyclin-dependent kinases]] CDK4 and CDK6.<ref name="a3">PMID:26264704</ref> See also [https://en.wikipedia.org/wiki/Abemaciclib Abemaciclib].		Abemaciclib, sold under the brand name Verzenio among others, is a medication for the treatment of advanced or metastatic breast cancers. It was developed by Eli Lilly and it acts as a CDK inhibitor selective for [[cyclin-dependent kinases]] CDK4 and CDK6.<ref name="a3">PMID:26264704</ref> See also [https://en.wikipedia.org/wiki/Abemaciclib Abemaciclib].